EUCTR2020-000126-26-FI进行中（未招募）1 期
A Hepatitis B Vaccine Challenge Study to Demonstrate the Durability of Protection Against Hepatitis B Virus Infection in Healthy Children Vaccinated Approximately 9 Years Previously With a 2- or 3-Dose Infant Series and Toddler Dose of Vaxelis® - A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc0 个研究点目标入组 200 人开始时间: 2020年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Is healthy (based on a review of medical history and targeted physical examination) based on the clinical judgment of the investigator
- •2. Has participated in Protocol V419-007 and received a 3 + 1 Vaxelis® schedule or participated in Protocol V419-008 and received a 2 + 1 Vaxelis® schedule
- •3. Is male or female, 8 years to 10 years of age, at the time of signing the informed consent/assent
- •4. The participant (or legally acceptable representative if applicable) provides written informed consent/assent for the study
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 200
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Has a history of diagnosis (clinical, serological, or microbiological) of HBV infection
- •2. Has a known or suspected impairment of immunological function (eg, HIV,splenectomy)
- •3. Has a known hypersensitivity to any component of the study vaccine
- •4. Has a known or suspected blood dyscrasias, leukemia, lymphomas of any type or other malignant neoplasms affecting the haematopoietic and lymphatic system
- •5. Has a bleeding disorder contraindicating intramuscular vaccinations
- •6. Had a recent febrile illness (defined as oral temperature =38.1°C [=100.5°F]; axillary temperature =37.8°C [=100.0°F]) occurring within 72 hours prior to receipt of study vaccine
- •7. Has received any hepatitis B vaccine after participation in Protocol V419-007 or V419-008
- •8. Is receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease
- •9. Meets one or more of the following systemic steroid exclusion criteria:
- •a. Has received any dose of systemic steroids within 7 days prior to entering study
- •b. Is expected to require systemic steroids =20 mg/day for =5 consecutive days through the course of the participant’s participation in the study
- •10. Has received any licensed, non-live vaccine within the 14 days before receipt of study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of any study vaccine. Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of any study vaccine or at least 15 days after receipt of any study vaccine
- •11. Has received any licensed live vaccine within 30 days before receipt of study vaccine or is scheduled to receive any live vaccine within 30 days following receipt of any study vaccine
- •12. Has received a blood transfusion or blood products, including immunoglobulins within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion
- •13. Has participated in another clinical study of an investigational product within 2 months before study vaccination at Visit 1 (Day 1) or plans to participate anytime during the duration of the current clinical study. Participants enrolled in observational studies may be included; these will be reviewed on a case-by-case basis for approval by the Sponsor
- •14. Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study
研究者
相似试验
已完成
不适用
A randomised trial of hepatitis B booster vaccination at the age of 13 to 15 years following infant vaccination to assess efficacy against hepatitis B infection and acute hepatitisHepatitis BISRCTN71271385Medical Research Council (MRC) (UK)500
进行中（未招募）
不适用
A clinical trial to study the optimal dose of Hepatitis B vaccine in Human Immunodeficiency Virus (HIV) infected childreCTRI/2016/01/006495Shahid Akhtar Siddiqui60
Unknown
1 期
A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHBChronic Hepatitis BNCT02615639Third Affiliated Hospital, Sun Yat-Sen University450
招募中
1 期
Clinical trial of HB vaccine against HBV infectioHBV infectionJPRN-jRCTs061180101Hiasa Yoichi100
尚未招募
不适用
Immunogenic response in children with hemophilia to Hepatitis B vaccine administered by subcutaneous versus intradermal route.CTRI/2019/12/022528niversity College of Medical Sciences and Guru Teg Bahadur Hospital